Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05150652 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
A Phase 2 study of Breast Cancer and Breast Carcinoma, sponsored by Irada Ibrahim-zada.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05150652: Active Phase 2 study of Breast Cancer and Breast Carcinoma, sponsored by Irada Ibrahim-zada.
NCT05150652 is a Phase 2 study of Breast Cancer and Breast Carcinoma that is active but no longer recruiting, run by Irada Ibrahim-zada. The registered enrollment target is 8 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05150652, a Phase 2 study of Breast Cancer and Breast Carcinoma, is active but no longer recruiting, sponsored by Irada Ibrahim-zada.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Primary Outcome
Evaluate the effect of neoadjuvant endocrine therapy (6-months course) on margin status of breast conservation surgery for women with early stage, low-risk breast cancer, defined as ER-positive, HER2-negative, node-negative breast carcinoma (single lesion only). Negative margin status is defined as no tumor on ink.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole 2.5mg
- DRUG Anastrozole 1mg
- DRUG Exemestane 25 mg
Study Locations (1)
Kentucky
- University of Kentucky Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2026-06-09 |
| Phase | Phase 2 |
What the registry record for NCT05150652 still lists
NCT05150652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Tamoxifen is the first listed.
NCT05150652 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT05150652 about?
NCT05150652 is a clinical study titled "Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer". The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
What is the current status of trial NCT05150652?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-02-18. Estimated completion is 2026-06-09.
What conditions does trial NCT05150652 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Carcinoma, HER2-Negative Breast Cancer, Node Negative Breast Cancer.
What interventions are being tested in trial NCT05150652?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole 2.5mg (DRUG), Anastrozole 1mg (DRUG), Exemestane 25 mg (DRUG).
Who is sponsoring clinical trial NCT05150652?
This trial is sponsored by Irada Ibrahim-zada, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05150652 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05150652's enrollment target sits among peer trials
8 1196th of 1224 higher than 24 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI